pharmaphorum

OCTOBER 27, 2021

Merck & Co has signed a licensing deal with the UN-backed Medicines Patent Pool (MPP) that could pave the way for generic companies to manufacture its much-anticipated oral antiviral for COVID-19. The agreement would provide royalty-free licenses to companies manufacturing molnupiravir – originally developed by Ridgeback Biotherapeutics – for distribution in 105 low- and middle-income countries around the world.

Hospitals 142

Hospitals 142

Pharma Times

OCTOBER 27, 2021

Novartis is eyeing approval for Kymriah to treat adult patients with relapsed or refractory follicular lymphoma

148

148

Outsourcing Pharma

OCTOBER 26, 2021

Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.

141

141

NY Times

OCTOBER 27, 2021

Scientists say the results of the latest research examining the inflammation-fighting qualities of fluvoxamine, capping similar smaller studies, could lead to new treatment guidelines.

Hospitals 98

Hospitals 98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

OCTOBER 27, 2021

Bayer’s two-year-old digital health collaboration with One Drop has borne its first fruit, an artificial intelligence-powered software module for preventing cardiovascular disease (CVD). The German pharmaceutical company has been working with New York-based One Drop on digital health products that span multiple therapeutic areas, including oncology and women’s health as well as CVD in the alliance , which was expanded last year in a $98 million deal.

Diabetes 119

Diabetes Pharmaceutical Companies Pharmaceutical Companies 119

Pharma Times

OCTOBER 29, 2021

Experts say that it is vital to ensure that every member who is eligible for a vaccine has received one

Vaccines 137

Vaccines 137

Outsourcing Pharma

OCTOBER 25, 2021

An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.

98

98

pharmaphorum

OCTOBER 25, 2021

Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objectives. Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote.

118

118

Pharma Times

OCTOBER 26, 2021

The drug acts by inhibiting SARS-CoV-2 from replicating in the human system

154

154

NY Times

OCTOBER 26, 2021

Once the experts weigh in, the Food and Drug Administration itself makes a decision and then a similar process happens at the Centers for Disease Control and Prevention.

Immunity 89

Immunity Immunization Vaccines 89

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Outsourcing Pharma

OCTOBER 26, 2021

Appili Therapeutics reports it has enrolled the last patient for its Phase III study of Avigan/Reeqonus (favipiravir), developed in alliance with AiPharma.

98

98

pharmaphorum

OCTOBER 26, 2021

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines. The company said in its third-quarter results statement that it was weighing options for Sandoz to “maximise shareholder value,” adding that could include retaining the business or a separation – which could involve a spin-off or outright sale.

Generic Medicine 112

Generic Medicine Vaccines 112

Pharma Times

OCTOBER 27, 2021

Partnership will see DNAe, Imperial College London and the University of Leicester collaborate on early detection of recurrent breast cancer

108

108

NY Times

OCTOBER 27, 2021

Health officials approved mix-and-match Covid booster shots, but didn’t say whether it’s better to switch vaccines or stick with your original shot.

Vaccines 94

Vaccines Immunity Immunization 94

Drug Channels

OCTOBER 25, 2021

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. This chart complements Follow the Dollar: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. To further help you understand this channel, I have also included a brief video to explain the buy-and-bill system.

Hospitals 74

Hospitals 74

pharmaphorum

OCTOBER 26, 2021

COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing. But can the Pharmaceutical Strategy for Europe help to redress the balance? Only sustainable, robust supply chains and business models will allow innovation to flourish, secure access to medicines, and minimise the industry’s impact on the environment.

Generic Medicine 109

Generic Medicine Biosimilars 109

Pharma Times

OCTOBER 29, 2021

The winners of the 2021 Clinical Researcher of the Year – The Americas have been announced, find out who emerged victorious

101

101

NY Times

OCTOBER 27, 2021

The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations.

98

98

Outsourcing Pharma

OCTOBER 25, 2021

A leader from the language and tech solutions firm explains how multilingual support can improve patient recruitment and other aspects of clinical trials.

98

98

pharmaphorum

OCTOBER 28, 2021

Groups representing the biopharma industry have welcomed an increase in health-specific R&D to £5 billion in the UK autumn budget, despite a longer timeline for reaching the target of £22 billion in overall R&D spending. The Association of the British Pharmaceutical Industry (ABPI) and BioIndustry Association (BIA) both said that the increase acknowledges the enormous contribution made by the life sciences sector in helping to limit the impact of the pandemic through the rapid developmen

Pharmaceutical Manufacturing 105

Pharmaceutical Manufacturing Vaccines 105

Pharma Times

OCTOBER 25, 2021

Javid also announced the government’s ‘five pillar’ plan for addressing COVID-19 during the challenging winter months

Vaccines 99

Vaccines 99

Pharma Marketing Network

OCTOBER 27, 2021

The healthcare burden continues to increase and the complexity continues to grow. There is a high volume of inefficiencies in the market, which is becoming increasingly fragmented due to the infusion of venture capital dollars over the last five-plus years and the thousands of start-up companies focused on addressing some aspect of healthcare. A digital platform typically refers to a digital service or digital product with an integrated business model and operational model.

Customer Service 59

Customer Service Communication Hospitals 59

Outsourcing Pharma

OCTOBER 26, 2021

According to a recent survey from Oracle Health Sciences, 97% of trial professionals say newly adopted approaches will stay in use as we move beyond COVID-19.

98

98

pharmaphorum

OCTOBER 25, 2021

Hard on the heels of some impressive clinical trial results, Luminopia has won FDA approval for its digital therapeutic (DTx) for amblyopia or lazy eye in children that is based on watching TV shows. The DTx is TV watching with a difference, of course – namely specially modified TV shows and movies that are viewed using a virtual reality headset designed to promote use of the weaker eye in amblyopia, which is a leading cause of vision loss in children.

Hospitals 102

Hospitals 102

Pharma Times

OCTOBER 25, 2021

Package was announced during a speech at the annual Conservative Party Conference in Manchester, UK

Packaging 114

Packaging 114

Drug Channels

OCTOBER 28, 2021

Today’s guest post comes from Megan Marchal, Clinical Pharmacist at CoverMyMeds. Megan shares the story of Sophia Garland, a young professional who is living with and learning to manage a chronic medical condition that requires specialty medication. To learn more about technology and access to specialty medications, read the CoverMyMeds Medication Access Report: Complex Care & Specialty Edition.

59

59

Outsourcing Pharma

OCTOBER 28, 2021

During OSPâs November 17 online event, a group of experts will offer insights, advice, and examples of solutions that put patients at the center of studies.

102

102

pharmaphorum

OCTOBER 26, 2021

The EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics’ much-anticipated oral antiviral molnupiravir as a treatment for COVID-19 in adults. Molnupiravir is already filed for approval in the US and Canada – where Merck is known as MSD – amid hopes that the drug could be used to protect vulnerable people with mild or moderate COVID-19 from developing severe disease with a drug that can be delivered outside the hospital.

Hospitals 101

Hospitals Compounding Diabetes 101

Pharma Times

OCTOBER 29, 2021

Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor for the alternative pathway of the complement system

94

94

Drug Channels

OCTOBER 27, 2021

Fortunately, Halloween can’t be scarier than any other day this year. So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! Brrr.did you hear that? It’s the biosimilar boom! Creepy! Scream as Blue Cross Blue Shield frightfully overpays hospitals Shocking!

Biosimilars 75

Biosimilars Hospitals Independent Pharmacies Drug Pricing 75

Outsourcing Pharma

OCTOBER 25, 2021

The radvocacy group is joining with the Rare Disease Diversity Coalition on an initiative to identify and overcome challenges faced by minority patients.

98

98

pharmaphorum

OCTOBER 25, 2021

Consumer DNA testing company 23andMe has signed a deal to acquire privately-held Lemonaid Health in a $400 million deal that marks a move into the online health sector. Lemonaid operates an on-demand platform for remotely accessing medical care and pharmacy services, including online consultations and prescription medicines delivery across the US. 23andMe – which went public earlier this year through a blank cheque company backed by Virgin Group founder Sir Richard Branson – is making 25% of the

Vaccines 101

Vaccines Drug Development 101

Pharma Times

OCTOBER 26, 2021

Tucatinib, a tyrosine kinase inhibitor, works by blocking a specific area of the HER2 gene in cancer cells

107

107

NY Times

OCTOBER 29, 2021

Las autoridades sanitarias de EE. UU. autorizaron la combinación de vacunas en la dosis de refuerzo contra la covid, pero no han indicado cuál es la mejor opción.

Immunity 55

Immunity Immunization Vaccines 55

Outsourcing Pharma

OCTOBER 28, 2021

An expert from the decentralized study solutions company shares perspectives on the importance of inclusivity and solutions that could improve representation.

59

59